Close Menu

NEW YORK – Predictive Oncology subsidiary Helomics has signed a pair of agreements to use its artificial intelligence-based platform in oncology decision making.

First, Helomics said today that it is partnering with the University of Pittsburgh Medical Center to use AI to potentially improve clinical decision making for ovarian cancer patients. In addition, Interpace Diagnostics said that it is working with Helomics to develop tools that diagnose and assess the risk of thyroid cancer.  

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

23andMe has a holiday popup shop at a mall and could open additional stores, Bloomberg reports.

By studying koalas and a retrovirus that infects them, researchers may have uncovered a new sort of 'immune response' that occurs at the genomic level, Agence France Presse reports.

NPR reports that the first person in the US given a gene editing-based therapy for a genetic disorder is heading home.

In Science this week: ancient genomes reveal social inequality within individual households, new method for quantifying genetic variation in gene dosage, and more.